Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles ha...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2007-02, Vol.68 (9), p.688-690
Hauptverfasser: HAU, P, KOCH, D, JAUCH, T, KOCH, H, BOGDAHN, U, HUNDSBERGER, T, MARG, E, BAUER, B, RUDOLPH, R, RAUCH, M, BRENNER, A, RIECKMANN, P, SCHUTH, J
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Aged
Antineoplastic Agents, Alkylating - administration & dosage
Biological and medical sciences
Brain Neoplasms - drug therapy
Brain Neoplasms - mortality
Dacarbazine - administration & dosage
Dacarbazine - analogs & derivatives
Disease-Free Survival
Feasibility Studies
Female
Glioma - drug therapy
Glioma - mortality
Humans
Immunomodulators
Longitudinal Studies
Male
Medical sciences
Middle Aged
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Neurology
Pharmacology. Drug treatments
Risk Assessment - methods
Risk Factors
Survival Analysis
Survival Rate
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.
ISSN:0028-3878
1526-632X
DOI:10.1212/01.wnl.0000255937.27012.ee